Patients struggle to find affordable insulin despite Eli Lilly price cap: Report

Uninsured Americans are still having challenges accessing affordable insulin, despite Eli Lilly's decision to cap its generic version, Lispro, at $25 per vial, according to a report Sen. Elizabeth Warren's office released July 13. 

The report was based on survey responses from more than 300 U.S. pharmacies. 

The average cost of Lispro for uninsured patients was $97.51 — nearly four times higher than the $25 price cap set by Eli Lilly. In addition, 42 percent of the surveyed pharmacies did not have the lower-priced generic in stock.

Eli Lilly, Sanofi and Novo Nordisk — the nation's three largest insulin manufacturers — all announced insulin price cuts in March. While most of these price drops take effect in late 2023 and 2024, Eli Lilly rolled out a cap for Lispro this May. 

Editor's note: Becker's has reached out to Eli Lilly for comment and will update the article as more information becomes available. 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars